Mechanisms coupling the mTOR pathway to chronic obstructive pulmonary disease (COPD) pathogenesis

Area of Science:

• Pulmonary Medicine
• Molecular Biology
• Cellular Signaling

Background:

• Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disease characterized by airflow limitation and inflammation.
• The Mammalian target of Rapamycin (mTOR) pathway regulates cellular processes like protein synthesis and metabolism.
• Dysregulation of mTOR signaling is implicated in COPD pathogenesis, including impaired autophagy and increased inflammation.

Purpose of the Study:

• To review the therapeutic potential of targeting the mTOR pathway for COPD treatment.
• To explore the role of mTOR in COPD pathophysiology, including its impact on cellular damage and inflammation.
• To discuss how mTOR inhibition might offer new therapeutic strategies for COPD.

Main Methods:

• Literature review of studies investigating the mTOR pathway in COPD.
• Analysis of the molecular mechanisms linking mTOR signaling to COPD.
• Examination of the effects of mTOR inhibitors, such as rapamycin, on COPD-related cellular processes.

Main Results:

• Dysregulated mTOR signaling impairs autophagy, leading to the accumulation of damaged cells and proteins, inflammation, and oxidative stress in COPD.
• Persistent mTOR activation contributes to pulmonary vascular remodeling and resistance in COPD.
• mTOR inhibition by rapamycin can prevent senescent cell buildup and protease release in COPD lungs.
• mTOR influences corticosteroid sensitivity in COPD by regulating histone deacetylases.
• Gut-lung axis dysbiosis in COPD is linked to mTOR pathway alterations.

Conclusions:

• Targeting the mTOR pathway represents a promising therapeutic strategy for COPD.
• Inhibiting mTOR may mitigate key pathological features of COPD, including inflammation, cellular senescence, and protease activity.
• Further research into the mTOR pathway and its modulation could lead to novel treatments for COPD, potentially addressing corticosteroid resistance and the gut-lung axis.